Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.38 |
| ▸ | CYP27A1 | Q02318 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12389088 | 0.90 | EPHX2 (0.44) | EPHX2KDM4EGLAMAPK14MPO | |
| SCHEMBL12389901 | 0.86 | SLC9A1 (0.47) | EPHX2 | |
| SCHEMBL12365375 | 0.85 | KDM4E (0.45) | KDM4EGLAMAPK14MPOAKR1C3 | |
| SCHEMBL12365047 | 0.84 | KDM4E (0.46) | KDM4ESRD5A2GLAMPOAKR1C3 | |
| SCHEMBL12389015 | 0.84 | LMNA (0.49) | KDM4EGLAMPOCA1CA2 | |
| SCHEMBL12389867 | 0.84 | RXRA (0.41) | SRD5A2MAPK14 | |
| SCHEMBL12365837 | 0.83 | KDM4E (0.45) | KDM4EMAPK14MPOAKR1C3CA1 | |
| SCHEMBL12389569 | 0.82 | SRD5A2 (0.46) | EPHX2MRGPRX4SRD5A2 | |
| SCHEMBL12365323 | 0.81 | KDM4E (0.43) | KDM4ESRD5A2GLAMPOAKR1C3 | |
| SCHEMBL12389608 | 0.80 | KDM4E (0.42) | KDM4EGLAMPOCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | EPHX2 1910/4885KDM4E 1455/4885MRGPRX4 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.